Newly approved pancreatic cancer drug shows promise in lung cancer
Patients prescribed the newly approved pancreatic cancer treatment Rasonque from Revolution Medicines face delays as insurance coverage takes weeks to catch up following the FDA greenlight. The drug, known generically as daraxonrasib, successfully targets proteins previously considered undruggable and offers hope for future approvals across various cancer types. While early trial data indicate the medication also shrinks lung tumors by targeting a broad range of RAS mutations, patients currently encounter administrative barriers before they can access the therapy.
What changed
Patients are experiencing delays accessing the newly approved drug as insurance providers take weeks to update coverage policies following the FDA decision.
Live updates
-
Revolution Medicines Drug Faces Insurance Hurdles After Approval
Patients prescribed the newly approved pancreatic cancer treatment Rasonque from Revolution Medicines face delays as insurance coverage takes weeks to catch up following the FDA greenlight. The drug, known generically as daraxonrasib, successfully targets proteins previously considered undruggable and offers hope for future approvals across various cancer types. While early trial data indicate the medication also shrinks lung tumors by targeting a broad range of RAS mutations, patients currently encounter administrative barriers before they can access the therapy.
Why it matters
Revolution Medicines seeks to expand the application of daraxonrasib to treat metastatic non-small cell lung cancer after findings appeared in the New England Journal of Medicine. Researchers Salman Punekar and Ron DePinho previously noted that the treatment initiates a new era for RAS-mutant forms of the disease. The success of the drug opens pathways for additional Ras-inhibitor candidates targeting multiple cancer varieties.
What is confirmed
- Patients learned it can take insurance coverage weeks to catch up after Rasonque won FDA approval.
- Rasonque is a pancreatic cancer drug developed by Revolution Medicines.
- The drug successfully targets undruggable proteins.
What to watch next
- Resolution of insurance coverage delays for patients seeking Rasonque
- Updates on Revolution Medicines seeking to expand drug applications to metastatic non-small cell lung cancer
confidence 100%Sources used for this update (7)
- www.statnews.com — A breakthrough pancreatic cancer drug won approval. They still struggle to access it
- www.chemistryworld.com — US approves pancreatic cancer treatment that targets ‘undruggable’ proteins
- jen.jiji.com — France, Renoir Museum theft carried out by professionals: 2 paintings in the hands of thieves
- www.mycentraloregon.com — New drug shows promise in reducing COPD symptoms in smokers, clinical trials show
- www.nbcnews.com — Mother speaks out after family exposed to rabid goats at petting zoo party
- www.nbcnews.com — Families in Nebraska say state is taking away vital Medicaid funds from disabled people
- www.today.com — See Al Roker and Dylan Dreyer ‘Buddy Up’ at an Aerial Yoga Studio
-
Pancreatic Drug Daraxonrasib Shows Promise in Lung Cancer
The targeted cancer treatment daraxonrasib, previously approved for metastatic pancreatic cancer, demonstrates potential in shrinking tumors among patients with lung cancer. Early trial data indicate the drug targets a broad range of RAS mutations through a novel mechanism. Revolution Medicines is actively seeking to expand the application of the medication to treat metastatic non-small cell lung cancer following findings published in the New England Journal of Medicine. Researchers Salman Punekar and Ron DePinho highlight the treatment as marking a new era for RAS-mutant forms of the disease, according to recent scientific commentary.
Why it matters
Revolution Medicines secured prior approval for daraxonrasib under the brand name Rasonque for pancreatic cancer patients. Investigators are now testing whether the targeted therapy can successfully treat other oncology indications, such as non-small cell lung cancer, which often features difficult RAS mutations. The therapy utilizes a novel mechanism to target these mutations.
What is confirmed
- Daraxonrasib is a newly approved drug for pancreatic cancer that shows potential in shrinking tumors in lung cancer patients.
- The drug targets a broad range of RAS mutations with a novel mechanism.
- New trial results indicate that daraxonrasib might also be beneficial for some patients with lung cancer.
What to watch next
- Regulatory decisions by the FDA regarding the expansion of daraxonrasib to treat lung cancer patients
- Further Phase 1/2 clinical trial data releases published in the New England Journal of Medicine
confidence 90%Sources used for this update (4)
- www.yahoo.com — Breakthrough Pancreatic Cancer Drug Shows Promise In Lung Cancer Trial
- jen.jiji.com — Ostia, blood on the street after the murder-suicide three days ago: residents in shock
- oncodaily.com — Salman Punekar and Ron DePinho: Daraxonrasib Marks a New Era for RAS-Mutant Non-Small Cell Lung Cancer
- www.ibtimes.com.au — Pancreatic Cancer Drug Daraxonrasib Shows Early Promise Shrinking Tumors In Lung Cancer Trial
-
FDA-Approved Pancreatic Cancer Drug Rasonque Shows Promise for Lung Cancer
The FDA has approved daraxonrasib, marketed as Rasonque by Revolution Medicines, for the treatment of metastatic pancreatic cancer. Early clinical data now suggest the drug may also be effective against metastatic non-small cell lung cancer. A Phase 1/2 clinical trial published in the New England Journal of Medicine indicates the drug can shrink tumors in patients with this specific type of lung cancer. While the drug is already approved for pancreatic use, Revolution Medicines is seeking to extend its application to lung cancer patients.
Why it matters
Rasonque is part of a class of RAS inhibitors targeting mutations common in several aggressive cancers. The drug's approval for pancreatic cancer followed a landmark trial led by Dana-Farber. Its potential expansion into lung cancer treatment could broaden the utility of the medication for a wider patient population.
What is confirmed
- The FDA approved daraxonrasib for metastatic pancreatic cancer.
- Revolution Medicines markets daraxonrasib under the brand name Rasonque.
- Phase 1/2 clinical data for Rasonque in metastatic non-small cell lung cancer were published in the New England Journal of Medicine.
- Early studies suggest Rasonque may be effective in treating lung cancer.
Still unconfirmed
- The drug costs $480,000 a year.
- The pancreatic cancer approval followed a landmark clinical trial led by Dana-Farber.
What to watch next
- FDA decision on expanding the Rasonque label to include non-small cell lung cancer
- Publication of further clinical trial data regarding tumor shrinkage rates in lung cancer patients
confidence 95%Sources used for this update (14)
- The New York Times — A $480,000-a-Year Pill Reflects a New Normal for Cancer Drugs
- ABC News - Breaking News, Latest News and Videos — Pancreatic cancer drug may hold promise for lung cancer as well, early study suggests
- Yahoo Finance — New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer
- News-Medical — FDA approves daraxonrasib for metastatic pancreatic cancer following landmark clinical trial led by Dana-Farber
- NBC News — Newly approved pancreatic cancer drug shows promise in lung cancer
- jen.jiji.com — School, new Coop campaign launched, focus on circular health
- jen.jiji.com — Back to school: ISS mini-guide for parents and children against anxiety
- abc7ny.com — Pancreatic cancer drug may hold promise for lung cancer as well, early study suggests
- www.today.com — How New Tech is Helping Aging Adults Stay in Their Home
- www.today.com — Surgeon Shares Latest in Prostate Cancer Treatments
- www.medpagetoday.com — Rare Brain Disorder Gets Its First FDA Drug Approval
- www.medpagetoday.com — Alcohol-Linked Cancer Deaths Rising